Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer
Zaineb Hassouneh, Onika D. V. Noel, Niannian Ji, Michelle E. Kim, Jordan Svatek, Robert S. Svatek, April L. Risinger, Neelam Mukherjee · 2024
Read Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer by Zaineb Hassouneh, Onika D. V. Noel, Niannian Ji, Michelle E. Kim, Jordan Svatek, Robert S. Svatek, April L. Risinger, Neelam Mukherjee (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11592921.txt.
Description
Zaineb Hassouneh and co-authors present a 2024 study on an old chemotherapy drug that wakes up natural killer cells against bladder cancer. Bladder tumors resist approved immunotherapy more than expected, and this team's earlier work showed killer cells drive patient survival. Screening approved drugs for one that fires those cells up surfaced eribulin, a microtubule blocker used in breast cancer.
Low doses sharpened the killer cells' movement and tumor killing in dishes, including samples from patients. Delivered into the bladder in mouse models, the drug shrank tumors and extended survival, and the benefit vanished without killer cells. Sequencing pointed at how the drug flips the cells' switches. Trials already testing eribulin in bladder cancer gain a mechanism to stand on.
Catalog record
| CREATOR | Zaineb Hassouneh, Onika D. V. Noel, Niannian Ji, Michelle E. Kim, Jordan Svatek, Robert S. Svatek, April L. Risinger, Neelam Mukherjee |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |